Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Nasopharyngeal Carcinoma Treated With External Radiotherapy, Brachytherapy, and Concurrent/Adjuvant Chemotherapy

DeNittis, Albert S., M.D.; Liu, Li, M.D.; Rosenthal, David I., M.D.; Machtay, Mitchell, M.D.

American Journal of Clinical Oncology: February 2002 - Volume 25 - Issue 1 - p 93-95

The standard treatment for advanced nasopharyngeal carcinoma (NPC) has become external beam radiation therapy (EBXRT) 70 Gy/7 weeks + 3 cycles of concurrent cisplatin followed by 2 to 3 cycles of adjuvant cisplatin/5-fluorouracil (5-FU). Some reports suggest that the addition of low-dose rate brachytherapy to EBXRT also improves local control. To our knowledge, this is the first report of the “triple” combination of EBXRT, brachytherapy, and concurrent/adjuvant chemotherapy. Eleven patients treated from 1992 to 1998 were evaluated. All patients had stage III/IV (excluding T4 lesions) NPC. Treatment consisted of EBXRT (64–70 Gy/7 weeks), followed by a brachytherapy boost (6–15 Gy delivered 0.5 cm deep to the mucosa). Chemotherapy consisted of concurrent cisplatin (100 mg/m2) and post-XRT adjuvant cisplatin (80 mg/m2) and 5-FU (1,000 mg/m2/day × 4 days) for 2 cycles. All 11 patients were evaluable. The average age was 44 years, and median follow-up was 38 months (range: 23–82 months). Median EBXRT dose was 66 Gy, and median brachytherapy dose was 9 Gy (median total dose: 75 Gy). All patients obtained primary tumor complete response (CR). Two patients required post-XRT neck dissection to achieve regional CR. To date, 10 patients are alive with no evidence of disease. The 3-year actuarial survival is 100%. One patient died at 82 months of a late distant recurrence (at 37 months post-XRT). No patient has had a local or neck failure. Chemoradiation plus brachytherapy offers encouraging survival and local–regional control. Further study of this regimen as an alternative or adjunct to intensity-modulated EBXRT is warranted.

From the Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A.

Address correspondence and reprint requests to Dr. Mitchell Machtay, Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, U.S.A.

Results of this article were presented in part at the Fifth International Conference on Head and Neck Cancer, July 2000, San Francisco, California, U.S.A.

© 2002 Lippincott Williams & Wilkins, Inc.